Short Interest in RCN Pareto Strategic Allocation ETF (NYSEARCA:PRTO) Decreases By 80.1%

RCN Pareto Strategic Allocation ETF (NYSEARCA:PRTO) saw a large decline in short interest in the month of August. As of August 14th, there was short interest totaling 287 shares, a decline of 80.1% from the July 30th total of 1,444 shares. Based on an average daily trading volume, of 113 shares, the days-to-cover ratio is currently 2.5 days. Currently, 0.0% of the company’s shares are short sold.

RCN Pareto Strategic Allocation ETF Price Performance

Shares of PRTO stock remained flat at $28.47 during trading hours on Wednesday. The stock had a trading volume of 108 shares. The business’s fifty day moving average is $27.71. The company has a market capitalization of $17.94 million, a price-to-earnings ratio of -29.66 and a beta of 1.07. RCN Pareto Strategic Allocation ETF has a one year low of $24.68 and a one year high of $28.58.

Proteon Therapeutics was a biopharmaceutical company focused on developing treatments for patients with kidney and vascular diseases. The company’s research and development efforts centered on therapies designed to address severe and life-threatening conditions, particularly those related to renal disease and vascular access for hemodialysis patients.

One of Proteon Therapeutics’ best-known product candidates was vonapanitase, an investigational enzyme developed to improve vascular access outcomes in patients with end-stage renal disease who require hemodialysis.